Esperion Therapeutics Files To Go Public, Seeking $70 MIllion
PLYMOUTH - Bad cholesterol-battling Esperion Therapeutics has filed for an initial public stock offering with the federal Securities and Exchange Commission to raise up to $70 million. Esperion is focused on drugs to treat high levels of low-density lipoprotein cholesterol, the so-called bad cholesterol, that can be taken in pill form, and which the company